Biosight Ltd.

Biosight Ltd. is a dynamic pharmaceutical company focused on developing innovative therapeutics for hematological malignancies and disorders. With a commitment to addressing unmet medical needs, Biosight Ltd. is dedicated to advancing patient care through cutting-edge research and development.

The company's lead product, BST-236 (aspacytarabine), is an innovative proprietary anti-metabolite designed to enable high-dose chemotherapy with reduced systemic toxicity. Currently, BST-236 is under investigation as a single agent in a Phase 2b trial for first-line treatment of acute myeloid leukemia (AML). Biosight Ltd. is located at 1 Hayarden St., Airport City P.O.B 1083, Lod, 7019802, IL.

Biosight Ltd. is positioned to make a significant impact on the landscape of hematological disease treatment. We invite the manager of Biosight Ltd. to create a customized and exclusive company showcase and product listing on our platform to further enhance your company's visibility and commercial opportunities.